An Economic Model to Compare the Different Empiric and First/Second Line Treatment Regimens for Suspected Methicillin-Resistant Staphylococcus Aureus Nosocomial Pneumonia.

No. of days in Hospital ICU_VAN Clinical efficacy_VAN No. of days in Hospital ICU_LIN Proportion of patients with MRSA confirmation Renal impairment_VAN Renal impairment_LIN Clinical efficacy_LIN No. of days on MV_VAN No. of days in Hospital Total_VAN Cost of Linezolid IV No. of days on MV_LIN No. of days of treatment No. of days in Hospital Total_LIN Additional days in hospital due to tx failure Inpatient cost per day (ICU) Days after which switch made to 2nd line due to failure/SAE Inpatient cost per day (general ward) Additional days in hospital due to SAE Cost of Vancomycin IV, 1gm SAE leading to discontinuation_VAN Cost for mechanical ventilation SAE leading to discontinuation_LIN Treatment failure factor for health utility Side effect factor for health utility OR of mortality related to discordant empiric tx Sensitivity Analysis on Incremental Cost per Patient; (VAN Vs. LIN)